{name}
{subtitle}
Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer
city
~26 mi. (Misterbianco, Italy, +153 more cities)
facility
Humanitas Istituto Clinico Catanese S.p.A - U.O. Oncologia Medica
condition
Bladder Urothelial Carcinoma, +2 more conditions
drug
BCG solution, +1 more drug
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~30 mi. (Catania, Italy, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Either Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
city
~30 mi. (Catania, Italy, +52 more cities)
facility
GSK Investigational Site
biomarker
BRCA1 Loss, +8 more biomarkers
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~98 mi. (Messina, Italy, +140 more cities)
facility
AOU Policlinico G. Martino ( Site 0324)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~98 mi. (Messina, Italy, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type